NY R & D UpdateBDAZ did a summary from the NY R & D meeting of trials and publications on Agora on Oct 13th at 2:35 PM. It is worth checking out.
The bottom line is that there will be 3 new trials launching in 2017 and we know that the BoM trial will be complete in 2018.
There are also activities on new compounds.
So I think the 2017 and 2018 years will be a very exciting period of discovery. Passing the futility analysis for apabetalone re BETonMACE in 2017 will also stimulate interest. Also if the zen3694 trial on mCRPC yields positive results the momentum may build with BP.
So we'll have an interesting 2 years coming up and it seems that the momentum is building behind epigenetics and BET inhibitors. This may continue to fuel interest from BP in RVX and Zenith.
If zen3694 is successful with mCRPC I feel Pfizer will take notice ...but then again I felt that AZ would take notice of the post hoc MACE results for rvx-208 given that RVX has a joint patent of rvx-208 (apabetalone) + rosuvastatin and nothing that I am aware of has happened there.
The share price is still well up from early September but sliding. Will a new licensing deal be announced soon??? I don't know.
GLTA